1. Volume 14, Issue 10, Pages 999-1008 (September 2013)
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial 
Prof Dr Susan G Kreissman, MD, Prof Robert C Seeger, MD, Prof Katherine K Matthay, MD, Wendy B London, PhD, Prof Richard Sposto, PhD, Prof Stephan A Grupp, MD, Prof Daphne A Haas-Kogan, MD, Prof Michael P LaQuaglia, MD, Prof Alice L Yu, MD, Prof Lisa Diller, MD, Allen Buxton, MS, Prof Julie R Park, MD, Prof Susan L Cohn, MD, Prof John M Maris, MD, Prof C Patrick Reynolds, MD, Prof Judith G Villablanca, MD 
The Lancet Oncology 
Volume 14, Issue 10, Pages (September 2013)
DOI: /S (13)
Copyright © 2013 Elsevier Ltd Terms and Conditions

2. Figure 1 Treatment schema
PBSC=peripheral blood stem cells. AHSCT=autologous haemopoietic stem-cell transplantation. CEM=carboplatin, etoposide, and melphalan. GFR=glomerular filtration rate. AUC=area under the curve. G-CSF=granulocyte colony-stimulating factor. ANC=absolute neutrophil count. MIBG=123I or 131I- meta-iodobenzylguanidine.
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2013 Elsevier Ltd Terms and Conditions

3. Figure 2
Trial profile
*372 patients (192 non-purged, 180 purged) received a transplant, including those who received the PBSC product to which they were allocated (randomised) and those who were crossovers. † One additional patient who received a transplant was retrospectively (post-transplant) determined by the treating institution to have had progressive disease at the end of induction; thus table 1 presents a total of 38 patients in the purged group with end of induction progressive disease. ‡Patients alive at last contact were censored in survival analysis.
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2013 Elsevier Ltd Terms and Conditions

4. Figure 3 Event-free survival and overall survival
(A) Event-free survival for intention-to-treat population from time of enrolment or randomisation. (B) Overall survival for intention-to-treat population from time of enrolment or randomisation. (C) Event-free survival for comparison of patients randomly assigned to purged treatment group versus patients randomly assigned to non-purged treatment group, from time of transplantation. (D) Overall survival for comparison of patients randomly assigned to purged treatment group versus patients randomly assigned to non-purged treatment group, from time of transplantation.
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2013 Elsevier Ltd Terms and Conditions

5. Figure 4 Event-free survival and overall survival by TLDA test results
(A) Event-free survival. (B) Overall survival. TLDA=TaqMan low density array. PBSC=peripheral blood stem cells.
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2013 Elsevier Ltd Terms and Conditions